公开(公告)号：US20220117991A1

公开(公告)日：2022-04-21

申请号：US17051549

申请日：2019-04-12

Applicant: Helperby Therapeutics Limited

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K31/7072 ,  A61K31/4178 ,  A61K31/55 ,  A61K31/665 ,  A61K31/545 ,  A61K31/431 ,  A61P31/04

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and an antimicrobial compound selected from nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, or a pharmaceutically acceptable derivative or prodrug thereof. These combinations are particularly useful for the treatment of microbial infections.

公开(公告)号：US10888575B2

公开(公告)日：2021-01-12

申请号：US16317512

申请日：2017-07-11

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K31/7072 ,  A61P31/04 ,  A61K31/407 ,  A61K38/12

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof, optionally with a polymyxin selected from polymyxin E and polymyxin or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

公开(公告)号：US10335454B2

公开(公告)日：2019-07-02

申请号：US15537007

申请日：2015-12-18

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K31/05 ,  A61K38/12 ,  A61K31/145 ,  A61K31/216 ,  A61K31/382 ,  A61K31/405 ,  A61K31/416 ,  A61K31/428 ,  A61K31/616 ,  A61K31/135 ,  A61K31/192 ,  A61K31/196 ,  A61K31/5415

Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US20240197767A1

公开(公告)日：2024-06-20

申请号：US17768669

申请日：2020-10-09

Applicant: Helperby Therapeutics Limited

Inventor： Professor Anthony Coates ,  Yanmin Hu

IPC: A61K31/7072 ,  A61K31/65 ,  A61P31/04

CPC classification number: A61K31/7072 ,  A61K31/65 ,  A61P31/04

Abstract: The present invention relates to a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a tetracycline antibiotic or a pharmaceutically acceptable derivative or prodrug thereof, for use in treating a microbial infection, particularly a bacterial infection such as a urinary tract infection.

公开(公告)号：US10736888B2

公开(公告)日：2020-08-11

申请号：US15770674

申请日：2016-10-20

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K9/00 ,  A61K31/4745 ,  A61P31/06 ,  A61P31/08 ,  A61K31/351 ,  A61K31/7036

Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US20230233559A1

公开(公告)日：2023-07-27

申请号：US17641257

申请日：2020-09-10

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Professor Anthony Coates ,  Yanmin Hu

IPC: A61K31/506 ,  A61K31/4725 ,  A61P31/04

CPC classification number: A61K31/506 ,  A61K31/4725 ,  A61P31/04

Abstract: The present invention relates to a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a fluoroquinolone antibiotic or a pharmaceutically acceptable derivative or prodrug thereof, for use in treating a microbial infection, particularly a bacterial infection such as a urinary tract infection.

公开(公告)号：US09757427B2

公开(公告)日：2017-09-12

申请号：US14772538

申请日：2014-03-20

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Yanmin Hu ,  Anthony Coates

IPC: A61K31/7072 ,  A61K38/12

CPC classification number: A61K38/12 ,  A61K31/7072 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483 ,  A61K2300/00

Abstract: The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and an anti-microbial agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and an anti-microbial agent for the treatment of microbial infections.

公开(公告)号：US09549965B2

公开(公告)日：2017-01-24

申请号：US14862108

申请日：2015-09-22

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Yanmin Hu ,  Anthony R M Coates

IPC: A61K38/12 ,  A61K31/138 ,  A61K31/18 ,  A61K31/395 ,  A61K31/417 ,  A61K31/475 ,  A61K31/517 ,  A61K45/06 ,  A61K31/05 ,  A61K31/10 ,  A61K31/167 ,  A61K31/216 ,  A61K31/282 ,  A61K31/305 ,  A61K31/382 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/445 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/5415 ,  A61K31/704 ,  A61K31/7052 ,  A61K33/24 ,  A61K38/14 ,  A61K31/145

CPC classification number: A61K38/12 ,  A61K31/05 ,  A61K31/10 ,  A61K31/138 ,  A61K31/145 ,  A61K31/167 ,  A61K31/18 ,  A61K31/216 ,  A61K31/282 ,  A61K31/305 ,  A61K31/382 ,  A61K31/395 ,  A61K31/407 ,  A61K31/417 ,  A61K31/4178 ,  A61K31/445 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/475 ,  A61K31/517 ,  A61K31/5415 ,  A61K31/704 ,  A61K31/7052 ,  A61K33/24 ,  A61K38/14 ,  A61K45/06 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483 ,  A61K2300/00

Abstract: The present invention relates to a combination comprising at least one compound selected from the group consisting of an α-adrenergic antagonist, an anthelmintic agent, an antifungal agent, an antimalarial agent, an antineoplastic agent, an antipsychotic agent, an antioxidant, a vasodilator, a vitamin, or a pharmaceutically acceptable derivative thereof; and an antimicrobial compound.

Abstract translation: 本发明涉及包含至少一种选自α-肾上腺素能拮抗剂，驱肠虫剂，抗真菌剂，抗疟剂，抗肿瘤剂，抗精神病药，抗氧化剂，血管舒张剂， 维生素或其药学上可接受的衍生物; 和抗微生物化合物。

公开(公告)号：US11951119B2

公开(公告)日：2024-04-09

申请号：US17051549

申请日：2019-04-12

Applicant: Helperby Therapeutics Limited

Inventor： Anthony Coates ,  Yanmin Hu

IPC: A61K31/7072 ,  A61K31/4178 ,  A61K31/431 ,  A61K31/545 ,  A61K31/55 ,  A61K31/665 ,  A61P31/04

CPC classification number: A61K31/7072 ,  A61K31/4178 ,  A61K31/431 ,  A61K31/545 ,  A61K31/55 ,  A61K31/665 ,  A61P31/04

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and an antimicrobial compound selected from nitrofurantoin, mecillinam, fosfomycin, cephalexin and faropenem, or a pharmaceutically acceptable derivative or prodrug thereof. These combinations are particularly useful for the treatment of microbial infections.

公开(公告)号：US20220257699A1

公开(公告)日：2022-08-18

申请号：US17630645

申请日：2020-07-28

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Professor Anthony Coates ,  Yanmin Hu

IPC: A61K38/12 ,  A61K31/7072 ,  A61K9/08 ,  A61P31/04

Abstract: The present invention relates to a pharmaceutical product in the form of a storage stable lyophilisate or a pharmaceutical formulation in the form of a sterile solution for parenteral administration. Both the lyophilisate and solution consist essentially of a polymyxin selected from polymyxin E, polymyxin B, or a pharmaceutically acceptable derivative thereof, and zidovudine or a pharmaceutically acceptable derivative thereof. The solution further includes an aqueous carrier.